Drugs Made In America Acquisition (DMAAR) Total Non-Current Liabilities (2025)
Drugs Made In America Acquisition (DMAAR) reported Total Non-Current Liabilities of $6.9 million for Q4 2025.
Drugs Made In America Acquisition (DMAAR) Total Non-Current Liabilities (2025) Analysis & Trends
Drugs Made In America Acquisition has reported Total Non-Current Liabilities for 1 years, with the latest figure at $6.9 million in Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities changed N/A year-over-year to $6.9 million; the trailing twelve-month figure through Dec 2025 stood at $6.9 million (changed N/A YoY), and the FY2025 full-year result was $6.9 million, changed N/A from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $6.9 million.
- The five-year high for Total Non-Current Liabilities was $6.9 million in Q4 2025, with the low at $6.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | EQV Ventures Acquisition | 477.69 Mn | 477.69 Mn | - | - |
| 2 | Berto Acquisition | 312.46 Mn | 312.46 Mn | - | - |
| 3 | Centurion Acquisition | 311.65 Mn | 311.65 Mn | - | - |
| 4 | GP-Act III Acquisition | 311.36 Mn | 311.36 Mn | - | - |
| 5 | Churchill Capital Corp IX | 310.79 Mn | 310.79 Mn | - | - |
| 6 | WEN Acquisition | 309.15 Mn | 309.15 Mn | - | - |
| 7 | Bold Eagle Acquisition | 275.54 Mn | 275.54 Mn | - | - |
| 8 | Soulpower Acquisition | 264.91 Mn | 264.91 Mn | - | - |
| 9 | BTC Development | 262.16 Mn | 262.16 Mn | - | - |
| 10 | Drugs Made In America Acquisition | - | - | - | 6.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.90 Mn |